Literature DB >> 26222991

Selective Heart Rate Reduction Improves Metabolic Syndrome-related Left Ventricular Diastolic Dysfunction.

Nassiba Merabet1, Yuehua Fang, Lionel Nicol, Christelle Monteil, Isabelle Rémy-Jouet, Jean-Paul Henry, Didier Wecker, Sabrina Le Bouter-Banon, Jerome Roussel, Vincent Richard, Christian Thuillez, Paul Mulder.   

Abstract

BACKGROUND: Enhanced heart rate observed in metabolic syndrome (MS) contributes to the deterioration of left ventricular (LV) function via impaired LV filling and relaxation, increased myocardial O2 consumption, and reduced coronary perfusion. However, whether heart rate reduction (HRR) opposes LV dysfunction observed in MS is unknown.
METHODS: We assessed in Zucker fa/fa rats, a rat model of MS, the cardiovascular effects of HRR induced by the If current inhibitor S38844 (3 mg · kg(-1) · d(-1)).
RESULTS: Delayed short-term (4 days) and long-term (90 days) HRR induced by S38844 reduced LV end-diastolic pressure and LV end-diastolic pressure-volume relation, increased myocardial tissue perfusion, decreased myocardial oxidized glutathione levels, and preserved cardiac output, without modifying LV end-systolic pressure and LV end-systolic pressure-volume relation, although only long-term S38844 opposed LV collagen accumulation. Long-term S38844 improved flow-induced endothelium-dependent dilatation of mesenteric arteries, while metabolic parameters, such as plasma glucose levels, and Hb1c, were never modified.
CONCLUSIONS: In rats with MS, HRR induced by the If inhibitor S38844 improved LV diastolic function and endothelium-dependent vascular dilatation, independent from modifications in metabolic status. Moreover, this improvement in cardiac function involves not only immediate effects such as improved myocardial perfusion and reduced oxidative stress but also long-term effects such as modifications in the myocardial structure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26222991     DOI: 10.1097/FJC.0000000000000294

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Diagnostic imaging in the management of patients with metabolic syndrome.

Authors:  Seo Rin Kim; Lilach O Lerman
Journal:  Transl Res       Date:  2017-11-22       Impact factor: 7.012

2.  Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome.

Authors:  Marianne Lachaux; Matthieu Soulié; Mouad Hamzaoui; Anaëlle Bailly; Lionel Nicol; Isabelle Rémy-Jouet; Sylvanie Renet; Cathy Vendeville; Pascale Gluais-Dagorn; Sophie Hallakou-Bozec; Christelle Monteil; Vincent Richard; Paul Mulder
Journal:  Endocrinol Diabetes Metab       Date:  2020-04-16

3.  Carotid Intima-Media Thickness as the Cardiometabolic Risk Indicator in Patients with Nonfunctional Adrenal Mass and Metabolic Syndrome Screening.

Authors:  Mehtap Evran; Gamze Akkuş; İlayda Berk Bozdoğan; Mustafa Gök; Ali Deniz; Murat Sert; Tamer Tetiker
Journal:  Med Sci Monit       Date:  2016-03-26

4.  Transient heart rate reduction improves acute decompensated heart failure-induced left ventricular and coronary dysfunction.

Authors:  Nicolas Peschanski; Najah Harouki; Matthieu Soulie; Marianne Lachaux; Lionel Nicol; Isabelle Remy-Jouet; Jean-Paul Henry; Anais Dumesnil; Sylvanie Renet; Françoise Fougerousse; Ebba Brakenhielm; Antoine Ouvrard-Pascaud; Christian Thuillez; Vincent Richard; Jérôme Roussel; Paul Mulder
Journal:  ESC Heart Fail       Date:  2021-01-20

5.  Effects of baseline heart rate at sea level on cardiac responses to high-altitude exposure.

Authors:  Jingdu Tian; Chuan Liu; Yuanqi Yang; Shiyong Yu; Jie Yang; Jihang Zhang; Xiaohan Ding; Chen Zhang; Rongsheng Rao; Xiaohui Zhao; Lan Huang
Journal:  Int J Cardiovasc Imaging       Date:  2020-01-17       Impact factor: 2.357

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.